A Third Recurrence: When Does Retreating SIBO Stop Being a Fresh Decision
A single patient, back in clinic for the third time in two years with the same bloating and diarrhea. The disagreement isn’t whether he has SIBO again — it’s whether that question is even still worth formally re-asking, or whether his anatomy has already answered it for good.
Tomás R., a 71-year-old retired postal worker, spent thirty-eight years sorting mail before an emergency ileocecal resection for a strangulated hernia six years ago left him with a surgically created blind loop where his terminal ileum was reconnected to his colon. He now spends most mornings on long walks with his dog through the same neighborhood he used to deliver mail on, walks that have gotten harder to finish over the past three weeks as bloating and watery diarrhea have crept back in — the same pattern that brought him in eighteen months ago, and again six months before that. Both prior episodes were confirmed by lactulose breath testing as methane-predominant small intestinal bacterial overgrowth, and both responded to a two-week course of rifaximin, with symptoms clearing within days each time — two documented monotherapy responses that sit awkwardly against the claim that methane-dominant disease responds poorly to rifaximin alone.
That third recurrence, on the same anatomic footing, is what actually divides the room. His blind loop is a structural abnormality that will not resolve — it is a fixed, permanent invitation for stasis and recolonization, meaning a fourth and fifth episode are not a possibility to plan around but close to a certainty. What the group doesn't have settled yet is whether his gas pattern has stayed the same. Methane-predominant overgrowth, driven by archaeal methanogens rather than hydrogen-producing bacteria, is the one subtype with direct comparative data behind a combination regimen — Low and colleagues found rifaximin paired with neomycin cleared methane in 87% of patients against 28% for rifaximin alone, and Pimentel and colleagues later reproduced a symptom advantage for the combination in a small randomized study. Two things about that evidence bear on Tomás specifically. It is thinner than "trial" makes it sound: Low is a retrospective chart review, and the randomized follow-up enrolled 31 patients. And both were done in constipation-predominant irritable bowel syndrome — not in a surgically created blind loop producing watery diarrhea, which is what his two prior breath tests were actually documenting. His methane-positive status is the only thing he shares with that population, and it is the thing the regimen difference turned on. Nothing about his symptoms alone can distinguish the two; only a repeat breath test can, and the cost of skipping it is a real chance of retreating him with a monotherapy regimen a trial has already shown underperforms for his prior phenotype.
GI clinic, third recurrence
I want to just retreat him with rifaximin today. This is his third identical episode on the same permanent anatomic defect — the blind loop isn’t going anywhere, and neither is his risk of recurrence. He responded well to rifaximin both prior times. Sending him for another breath test, waiting on results, and bringing him back before starting treatment adds delay and cost for a pattern that’s already told us what’s happening.
I’d want the breath test first, and it’s not just process for its own sake. Both his prior episodes were methane-dominant, and methane-predominant overgrowth is the one subtype where we have direct comparative data — Low’s series put methane clearance at 87% with rifaximin plus neomycin against 28% with rifaximin alone. I’ll concede what that data isn’t: it’s a chart review, the randomized follow-up was 31 patients, and all of it was done in constipation-predominant IBS, not in a blind loop. But if his gas pattern is still methane-dominant, treating with rifaximin alone risks giving him the weaker regimen when a better one is at least plausibly available.
I don’t think the recurrence pattern being predictable makes the regimen choice a formality — predictable that he’ll recur is not the same as predictable which gas his overgrowth will be producing this time.
I think you’re both right about different parts of this, and neither position actually resolves the thing that matters most for his next five years: this is his third episode in two years on a permanent structural defect. At some point, deciding fresh each time whether to test and which regimen to use stops being the efficient approach and starts being a series of identical decisions made one at a time.
For today, I’d side with repeating the breath test — the gastroenterologist’s point about methane-dominant disease needing a different regimen is a real, evidence-grounded reason, not caution for its own sake — even conceding, as he did, that the evidence is retrospective and borrowed from a constipation population. But I’d also want us to leave this visit with an actual standing plan: if he’s back with the same symptom pattern within a defined window next time, does he get retested every time, or does his surgical anatomy and two confirmed methane-dominant episodes earn him a pre-agreed empiric rifaximin-plus-neomycin retreatment without another round-trip through testing? That’s a real decision this group hasn’t made yet, and I don’t think it should stay undecided by default.
Agreed: repeat breath test today before retreating, with the regimen chosen by its result — rifaximin alone if hydrogen-predominant, rifaximin plus neomycin if methane-predominant confirmed again.
Not agreed: whether this is the last time he needs a fresh test-then-treat cycle. The pharmacologist proposed a standing pre-agreed retreatment plan for any future recurrence within a defined window; the gastroenterologist wants at least one more confirmed methane-pattern result before committing to skip testing on a future episode.